YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAM

耶鲁大学癌症中心卡拉布雷西免疫肿瘤学培训计划

• 批准号: 10646793
• 负责人: Harriet M. Kluger
• 金额: $ 58.24万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-03-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10646793
• 关键词: Acceleration; Address; Adjuvant; Appointment; Area; Biology; Cell Therapy; Clinical; Clinical Research; Clinical Trials Design; Community Outreach; Doctor of Philosophy; Drug Combinations; Drug toxicity; Eligibility Determination; Enrollment; Faculty; Funding; Grant; Home; Immunobiology; Immunology; Immunooncology; Immunosuppression; Immunotherapy; Individual; Institution; Laboratory Research; Mentors; Mentorship; Oncology; Play; Records; Research; Research Personnel; Research Project Grants; Resistance; Time; Training; Training Programs; Training and Education; Translational Research; Yale Cancer Center; cancer immunotherapy; cancer research center director; cancer type; clinical center; clinical investigation; clinically relevant; community engagement; curriculum development; gateway course; immunomodulatory therapies; medical schools; patient oriented; patient oriented research; pre-clinical; programs; response; synergism; translational immunology; trial design; tumor immunology; tumor microenvironment

Summary: Therapy for multiple types of cancer has evolved dramatically in the last decade with the emergence of immune modulation therapies that induce responses and prolong survival in the adjuvant and metastatic settings. It is now apparent that these advances are only the vanguard in a rapidly evolving field. Investigators from Yale School of Medicine have played key roles in both pre-clinical and clinical advances in immuno- oncology. Continued advancement requires better understanding of primary and secondary resistance to immune therapy, the biology of immune suppression in the tumor microenvironment, rational drug combinations, studies of drug toxicities and new trial designs specific for immune therapies. Hence, there is an urgent need to train junior investigators to conduct patient-oriented cancer immunology and immunotherapy studies to further accelerate these advances. Our Immuno-Oncology Training Program (IOTP) addresses this critical need by training MD or MD/PhD Scholars in clinically-relevant immuno-oncology and translational immunology. At least five junior faculty scholars are enrolled at any given time. IOTP is distinct from existing training programs at Yale as it is the only one to specifically focus on training of junior faculty in patient-oriented research in immuno- oncology and immunotherapy. IOTP has been highly successful to date in developing a diverse pool of independently funded researchers who capitalize on the wealth of expertise at our institution in immunobiology and immunotherapy. IOTP faculty have extensive track records of mentorship and are actively pursuing research in these areas. IOTP is supported by the Yale Cancer Center (YCC) and synergizes with the Yale Center for Clinical Investigation, home to our CTSA grant, which provides some foundational courses. Key distinguishing features or IOTP are didactic and practical training developed specifically for this program including courses on basic immunology and cancer immunology, immunotherapy-specific clinical trial design, the Cancer Immunology Forum and an individually tailored, two-year Translational Immuno-oncology research project encompassing laboratory and/or clinical research. New for the next funding period include a course on computational immunology, endeavors for training in mentorship and community outreach and engagement initiatives. Each scholar has a panel of mentors. Junior faculty within five years of appointment at Yale School of Medicine are eligible, with up to five scholars appointed at any one time, and an additional scholar will be funded by YCC. The program is led by an Executive Committee comprised of the PI (Dr. Harriet Kluger, YCC Associate Cancer Center Director for Education and Training), the Co-Director, Dr. Diane Krause, MD, PhD, an expert on cellular therapies, David Stern, PhD, Chair for Curriculum Development and Roy Herbst, MD, PhD, Chief of Oncology and Associate Cancer Center Director for Translational Research. In summary, the IOTP draws upon an area of profound institutional strength and enables YCC to focus specifically on cross-disciplinary training of scholars in Cancer Immunotherapy to meet the increasing need for cancer immunology experts and researchers.

摘要：在过去十年中，随着癌症的出现，多种类型癌症的治疗方法取得了巨大进展。 诱导反应并延长佐剂和转移细胞生存期的免疫调节疗法 设置。现在很明显，这些进步只是快速发展领域的先锋。调查员 耶鲁大学医学院的博士生在免疫学的临床前和临床进展中发挥了关键作用 肿瘤学。持续的进步需要更好地了解主要和次要的抵抗力 免疫治疗、肿瘤微环境中免疫抑制的生物学、合理的药物组合、 药物毒性研究和针对免疫疗法的新试验设计。因此，迫切需要 培训初级研究人员进行以患者为导向的癌症免疫学和免疫治疗研究，以进一步 加速这些进步。我们的免疫肿瘤学培训计划 (IOTP) 通过以下方式解决了这一关键需求 对临床相关免疫肿瘤学和转化免疫学领域的医学博士或医学博士/博士学者进行培训。至少 任何特定时间都会招收五名初级教师学者。 IOTP 与耶鲁大学现有的培训项目不同 因为它是唯一一个专门专注于培训初级教师进行以患者为导向的免疫研究的培训的机构 肿瘤学和免疫治疗。迄今为止，IOTP 在开发多样化的池方面取得了巨大成功 独立资助的研究人员利用我们机构在免疫生物学领域的丰富专业知识 和免疫疗法。 IOTP 教师拥有丰富的指导记录，并正在积极开展研究 在这些领域。 IOTP 得到耶鲁大学癌症中心 (YCC) 的支持，并与耶鲁大学癌症中心协同作用 临床研究是我们 CTSA 资助的所在地，提供一些基础课程。关键区别 功能或 IOTP 是专门为此计划开发的教学和实践培训，包括以下课程： 基础免疫学和癌症免疫学、免疫治疗特异性临床试验设计、癌症免疫学 论坛和单独定制的为期两年的转化免疫肿瘤学研究项目包括 实验室和/或临床研究。下一个资助期的新内容包括计算课程 免疫学，努力进行指导培训以及社区外展和参与活动。每个 学者有一个导师小组。耶鲁大学医学院任命五年内的初级教师是 符合资格，一次最多任命五名学者，YCC 将资助一名额外的学者。这 计划由执行委员会领导，执行委员会由 PI（YCC 副癌症中心 Harriet Kluger 博士）组成 教育和培训主任），联合主任 Diane Krause 博士，医学博士，博士，细胞专家 课程开发主席 David Stern 博士和肿瘤科主任 Roy Herbst 医学博士、哲学博士 和癌症中心转化研究副主任。总之，IOTP 利用了以下领域： 深厚的机构实力，使YCC能够专注于跨学科学者的培养 癌症免疫疗法可满足癌症免疫学专家和研究人员日益增长的需求。

项目成果

STING enhances cell death through regulation of reactive oxygen species and DNA damage.

• DOI: 10.1038/s41467-021-22572-8
• 发表时间: 2021-04-19
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Hayman TJ;Baro M;MacNeil T;Phoomak C;Aung TN;Cui W;Leach K;Iyer R;Challa S;Sandoval-Schaefer T;Burtness BA;Rimm DL;Contessa JN
• 通讯作者: Contessa JN

Targeting ferroptosis to treat colorectal cancer.

• DOI: 10.1016/j.tcb.2022.11.003
• 发表时间: 2022-12
• 期刊: Trends in cell biology
• 影响因子: 19
• 作者: Hong Yan;R. Talty;C. Johnson

Effect of exercise on peritoneal microenvironment and progression of ovarian cancer.

• 发表时间: 2021
• 期刊: American journal of cancer research
• 影响因子: 5.3
• 作者: M. J. Morrisson;Fangfang Bi;Kevin Yang;S. Cady;T. Hartwich;Alexandra P Cerchia;Zhigui Li;Jaeyeon Kim;M. Irwin;Yang Yang-Hartwich-Yang

Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma.

尽管采用多模式治疗复发性儿童胶质母细胞瘤，但 STAG2 突变仍持续存在。

• DOI: 10.1038/s41525-020-0130-7
• 发表时间: 2020
• 期刊: NPJ genomic medicine
• 影响因子: 5.3
• 作者: Hong,ChristopherS;Vasquez,JuanC;Kundishora,AdamJ;Elsamadicy,AladineA;Beckta,JasonM;Sule,Amrita;Marks,AsherM;Leelatian,Nalin;Huttner,Anita;Bindra,RanjitS;DiLuna,MichaelL;Kahle,KristopherT;Erson-Omay,EZeynep
• 通讯作者: Erson-Omay,EZeynep

Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis.

• DOI: 10.1016/j.ctro.2020.12.003
• 发表时间: 2021-03
• 期刊: Clinical and translational radiation oncology
• 影响因子: 3.1
• 作者: Miccio JA;Talcott WJ;Patel T;Park HS;Cecchini M;Salem RR;Khan SA;Stein S;Kortmansky JS;Lacy J;Narang A;Herman J;Jabbour SK;Hallemeier CL;Johung K;Jethwa KR
• 通讯作者: Jethwa KR